Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03825250
Other study ID # 0667
Secondary ID 2018-002076-4124
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date November 6, 2018
Est. completion date October 7, 2024

Study information

Verified date November 2023
Source University of Leicester
Contact Marius Roman, MD
Phone +44(0)1162525841
Email mariusroman@nhs.net
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The Val-CARD trial aims to answer the question: "Does the drug sodium valproate reduce complications affecting the heart and kidneys in patients having heart operations?" Sodium valproate is a drug commonly used in the treatment of epilepsy. Recently it has been shown to protect against heart and kidney damage in laboratory tests. This has led to trials evaluating whether it can prevent heart and kidney damage in patients. The investigators wish to evaluate whether treatment with sodium valproate for a short period can reduce levels of organ damage following heart surgery by measuring this in blood tests, exercise tests, a special x-ray measuring body fat content, a walk exercise and muscle strength tests. The investigators now want to establish if sodium valproate works by making the heart and kidney more resistant to any injury that results from the use of the heart lung machine.


Description:

This trial is a single centre, unblinded, randomised controlled trial of pre-surgery sodium valproate versus standard care (no treatment). The trial has two phases. In the first phase - the dose finding phase, 40 patients will be randomised (1:1:1:1) to three different treatment doses versus a control group of standard care (no treatment). A single sodium valproate dose will be selected based on the evaluation of compliance, toxicity and levels of Histone Deacetylase inhibition. In the second phase, the efficacy of this dose at preventing myocardial and kidney injury will then be compared to untreated controls using a 1:1 randomised parallel group design in a further 82 patients. In an optional research procedure during the efficacy phase of the trial (Phase 2) cardiometabolic status (cardiac function and visceral adiposity) will be evaluated using MRI scanning. Patients will be screened by the investigators to assess eligibility for entry into the trial. Eligible patients undergoing cardiac surgery with CPB who consent to participate will be randomly allocated using concealed allocation as follows: In the dose finding phase of the trial patient will be randomised in a 1:1:1:1 ratio to: 1. GROUP A: Standard care (no treatment) 2. GROUP B: Sodium valproate at a target dose of 15 mg/kg per day for 1-2 weeks pre-surgery. 3. Group C: Sodium valproate at a target dose of 15 mg/kg per day for 4-6 weeks pre-surgery. 4. Group D: Sodium valproate at a target dose of 25 mg/kg per day for 4-6 weeks pre-surgery. In the efficacy phase of the trial patients will be randomised in a 1:1 ratio to: 1. GROUP A: Standard care (no treatment) 2. GROUP B, C or D: Sodium valproate at a target dose as determined by the dose finding phase of the trial. The Val-CARD Trial proposes to test the overarching hypothesis that pre-surgery administration of sodium valproate will protect patients against organ damage that occurs during cardiac surgery with cardiopulmonary bypass. The trial will test a number of specific hypotheses: 1. Pre-surgery sodium valproate will reduce the risk of post cardiac surgery organ failure. 2. Short-term (1-2 weeks) pre-surgery treatment with sodium valproate at a target dose of 15mg/kg/day will have different pharmacokinetics but comparable tolerability and protective effects on myocardial and renal signaling to long-term (4-6 weeks) treatment at a target dose of 15mg/kg/ day or 25mg/kg/day. 3. Sodium valproate will reduce the risk of post cardiac surgery myocardial injury by increasing the expression of genes that promote myocardial mitochondrial homeostasis via effects on chromatin histone deacetylation. 4. Sodium valproate will reduce the risk of post cardiac surgery acute kidney injury (AKI) by increasing the expression of genes that promote renal tubular homeostasis. 5. Sodium valproate will reduce the risk of post cardiac surgery endothelial dysfunction by increasing the expression of genes that promote endothelial homeostasis. 6. The trial interventions will be tolerated by patients and will not result in long-term adverse changes in cardiometabolic status.


Recruitment information / eligibility

Status Recruiting
Enrollment 122
Est. completion date October 7, 2024
Est. primary completion date October 7, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adult cardiac surgery patients (=18 years) undergoing cardiac surgery (CABG, Valve, or CABG and Valve) with cardiopulmonary bypass (CPB). - Able, in the opinion of the investigator, and willing to give informed consent. Exclusion Criteria: - Emergency or salvage procedure - Patients with end stage renal failure defined as an estimated Glomerular Filtration rate (eGFR) <15 mL/min/1.72 m2 calculated from the Modification of Diet in Renal Disease equation,1 or patients who are on long-term haemodialysis or have undergone renal transplantation. - Patients with persistent or chronic atrial fibrillation. - Patients with acute liver disease. - Personal or family history of severe hepatic dysfunction, especially drug related. - Patients allergic to sodium valproate. - Patients with thrombocytopaenia (platelet count <150x109 per mL). - Patients taking long-term Histone Deacetylase Inhibitors such as sodium valproate. - Patients taking any of the following medications: antipsychotics, MAO inhibitors, antidepressants and benzodiazepines, Lithium, Olanzepine, Phenobarbital, Primidone, Phenytoin, Carbamazepine, Lamotrigine, Felbamate. - Patients diagnosed with a mitochondrial deficiency disorder. - Patients with porphyria. - Patients with known urea cycle disorders. - Women of child bearing potential (WOCBP) are excluded from the study. A woman is defined as being of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal, unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. - Patients who are participating in another interventional clinical trial. - Unable, in the opinion of the investigator, or unwilling to give informed consent protocol.

Study Design


Intervention

Drug:
Sodium Valproate
Treatment with Sodium Valproate vs. Control Discovery phase - 4 arms: 15 mg/kg for 1-2 weeks; 15mg/kg for 4-6 weeks; 25 mg/kg for 4-6 weeks; Control Efficiency phase - 2 arms: Treatment group selected from previous phase; Control

Locations

Country Name City State
United Kingdom Glenfield Hospital Leicester Leicestershire

Sponsors (1)

Lead Sponsor Collaborator
University of Leicester

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change of Serum Creatinine level Measurement of serum creatinine level and expressed as umol/L. Baseline, 2 weeks, 4 weeks, 0-6, 6-12, 24, 48, 72, and 96 hours post-operatively
Primary Change of Serum Troponin I level Measurement of serum Troponin level and expressed as ng/L. Baseline, at 0-6, 6-12, 24, 48 and 72 hours post-operatively
Secondary Change in Multiple organ dysfunction - Sepsis-related Organ Failure Assessment (SOFA) Score) Range 0-3, 3 being the worse score Baseline, 4 weeks, 0-6, 24, 48, 72 and 96 hours
Secondary NGAL (Neutrophil gelatinase associated lipocalcin) Measurement of NGAL level and expressed as µg/L. Baseline, day before surgery, 6-12, 24 and 48 hours post-surgery.
Secondary Lung Injury - Arterial alveolar oxygen (PaO2/FiO2) ratios Measurement of PaO2/FiO2 ratio and expressed in kPa/L. Baseline, day before surgery, 24, 48, 72 and 96 hours post-surgery.
Secondary AST (Aspartate Transaminase) Measurement of AST levels in serum and expressed in IU/L. Acute liver injury will be defined as an acute derangement of three times the upper limit of normal. Baseline, day before surgery, 0-6, 6-12, 24, 48, 72 and 96 hours post-surgery
Secondary ALT (Alanine Transaminase) Measurement of ALT levels in serum and expressed in IU/L. Acute liver injury will be defined as an acute derangement of three times the upper limit of normal. Baseline, day before surgery, 0-6, 6-12, 24, 48, 72 and 96 hours post-surgery
Secondary Bilirubin Measurement of Bilirubin levels in serum and expressed in µmol/L. Acute liver injury will be defined as an acute derangement of three times the upper limit of normal. Baseline, day before surgery, 0-6, 6-12, 24, 48, 72 and 96 hours post-surgery
Secondary Alkaline Phosphatase Measurement of Alkaline Phosphatase levels in serum and expressed in IU/L. Acute liver injury will be defined as an acute derangement of three times the upper limit of normal. Baseline, day before surgery, 0-6, 6-12, 24, 48, 72 and 96 hours post-surgery
Secondary Serum Amylase Measurement of Amylase levels in serum and expressed in IU/L. Acute pancreatitis will be defined as a serum amylase concentration >1000 ng/ml. Baseline, day before surgery, 0-6, 6-12, 24, 48, 72 and 96 hours post-surgery
Secondary Assessment of resource use - Time until extubation Time (hours) measured from the start of surgery - to extubation (up to 30 days)
Secondary Length of stay in Intensive Care Unit Number of hours between admission and discharge from the Intensive Care Unit (ICU). Time (hours) measured from the start of surgery to discharge from ICU (up to 30 days)
Secondary Length of Stay in Hospital Number of days between the date of surgery and discharge from the hospital. Time (days) measured from the start of surgery to discharge from hospital (up to 90 days)
Secondary Sepsis Sepsis is defined as: Suspected or documented infection and an acute change in total Sepsis-related Organ Failure Assessment (SOFA) score =2 points consequent to the infection. Range of SOFA is 0 to 3, 3 being the worse score. Baseline, 4 weeks before surgery, 0-6, 6-12, 24, 48, 72 and 96 hours post-surgery
Secondary Rate of mortality Rate of mortality at 30-day and 1 year from the date of surgery. Within 30-days from surgery and at 1 year from surgery
Secondary Bleeding and Transfusion The total number of units of red cells and other blood components transfused during the operative period and post-operative hospital stay Intra-operative and between time of surgery and hospital discharge up to two weeks
Secondary Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 Adverse events as assessed for type and severity by CTCAE v4.0 Post-operative up to 3 months follow-up from time of surgery
Secondary Mechanism study: Mithocondrial function of microvessels from tissue biopsies 50-100 mg biopsies obtained from pedicled left internal mammary artery biopsies. The mitochondrial function will be measured through the Bioenergetic Health Index. The Bioenergetic Health Index (BHI) is calculated using the following formula: BHI=(ATP-linked×reserve capacity)/(proton leak×non-mitochondrial) - as described by Chacko et al. The expected range is 0-100. At time of surgery
Secondary Mechanism study: microRNAs isolation from microvessels The findings will be represented by the frequency (%) of identified microRNAs. 50-100 mg biopsies obtained from pedicled left internal mammary artery biopsies. At time of surgery
Secondary Mechanism study: Chromatin Immunoprecipitation (ChIP) of microvessels from tissue biopsies To identify protein binding sites that may help identify functional elements in the genome.
Findings will be represented by the number (n) of binding sites. 50-100 mg biopsies obtained from pedicled left internal mammary artery biopsies.
At time of surgery
Secondary Mechanism study: Mithocondrial function measured in right atrium myocardium tissue biopsies 50-100 mg myocardial biopsies will be obtained from the right atrium at surgery. The mitochondrial function will be measured through the Bioenergetic Health Index. The Bioenergetic Health Index (BHI) is calculated using the following formula: BHI=(ATP-linked×reserve capacity)/(proton leak×non-mitochondrial) - as described by Chacko et al. The expected range is 0-100. At time of surgery
Secondary Mechanism study: microRNA isolation from right atrium myocardium tissue biopsies 50-100 mg myocardial biopsies will be obtained from the right atrium at surgery. The findings will be represented by the frequency (%) of identified microRNAs. At time of surgery
Secondary Mechanism study: Chromatin Immunoprecipitation (ChIP) in right atrium myocardium tissue biopsies 50-100 mg myocardial biopsies will be obtained from the right atrium at surgery. To identify protein binding sites that may help identify functional elements in the genome.
Findings will be represented by the number (n) of binding sites.
At time of surgery
Secondary Mechanism study: Mithocondrial function measured in adipose tissue biopsies Adipose tissue collected from epicardial fat at time of surgery. The mitochondrial function will be measured through the Bioenergetic Health Index. The Bioenergetic Health Index (BHI) is calculated using the following formula: BHI=(ATP-linked×reserve capacity)/(proton leak×non-mitochondrial) - as described by Chacko et al. The expected range is 0-100. At time of surgery
Secondary Mechanism study: microRNA isolation in adipose tissue biopsies Adipose tissue collected from epicardial fat at time of surgery. The findings will be represented by the frequency (%) of identified microRNAs. At time of surgery
Secondary Mechanism study: Chromatin Immunoprecipitation (ChIP) in adipose tissue biopsies Adipose tissue collected from epicardial fat at time of surgery. To identify protein binding sites that may help identify functional elements in the genome.
Findings will be represented by the number (n) of binding sites.
At time of surgery
Secondary Mechanism study: Measurement of microvesicles in urine samples Identification of microvesicles. The findings will be represented by the frequency (%) of each identified microvesicle. 1 day before surgery, 12 and 24 hours following surgery
Secondary Mechanism study: Measurement of microRNAs in urine samples The findings will be represented by the frequency (%) of identified microRNAs. 1 day before surgery, 12 and 24 hours following surgery
Secondary Mechanism study: Measurement of histone acetylation in urine samples The findings will be reported as acetylated H3 (ug/mg) over time (hours) 1 day before surgery, 12 and 24 hours following surgery
Secondary Mechanism study: Measurement of gene expression in urine samples Whole genome sequencing will be achieved through ATAC sequencing. The identified genes will be characterised by average expression count over ATAC. 1 day before surgery, 12 and 24 hours following surgery
Secondary Mechanism study: Cardiac Magnetic Resonance Imaging - Cardiac Function Assessment of cardiac function, by assessing ventricular function. This will be expressed as ejection fraction (%). Intravenous contrast will be administered via an indwelling venous catheter. Baseline, 1 day before surgery and 3 months following surgery
Secondary Mechanism study: Cardiac Magnetic Resonance Imaging - Cardiac adiposity content Assessment of cardiac adiposity content. A percentage of adipose tissue over total body mass will be calculated. Intravenous contrast will be administered via an indwelling venous catheter. Baseline, 1 day before surgery and 3 months following surgery
Secondary Mechanism study: Cardiac Magnetic Resonance Imaging - Visceral adiposity content Assessment of visceral adiposity content. A percentage of adipose tissue over total body mass will be calculated. Intravenous contrast will be administered via an indwelling venous catheter. Baseline, 1 day before surgery and 3 months following surgery
See also
  Status Clinical Trial Phase
Recruiting NCT06030596 - SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
Completed NCT04080700 - Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
Recruiting NCT03810599 - Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study N/A
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT05308719 - Nasal Oxygen Therapy After Cardiac Surgery N/A
Recruiting NCT04242134 - Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions N/A
Completed NCT04556994 - Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients. N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Recruiting NCT05023629 - STunning After Balloon Occlusion N/A
Completed NCT04941560 - Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
Completed NCT04006288 - Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Phase 4
Completed NCT01860274 - Meshed Vein Graft Patency Trial - VEST N/A
Recruiting NCT06174090 - The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients N/A
Completed NCT03968809 - Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
Terminated NCT03959072 - Cardiac Cath Lab Staff Radiation Exposure
Recruiting NCT05065073 - Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography Phase 4
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Completed NCT05096442 - Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions N/A